FDA Approves CEPHALEXIN — Aurobindo Pharma Limited

# FDA Approves Aurobindo Pharma's Cephalexin Oral Formulation The U.S. Food and Drug Administration has approved Aurobindo Pharma Limited's abbreviated new drug application (ANDA213568) for cephalexin oral tablets, expanding the generic antibiotic market and potentially intensifying price competition in the cephalosporin segment. This approval enhances Aurobindo's portfolio in the high-volume generic oral antibiotic market and provides additional revenue opportunities in a therapeutic category with substantial demand across healthcare providers.